Optimizing thiopurine therapy in inflammatory bowel disease

Jean Baptiste Chevaux, Laurent Peyrin-Biroulet, Miles P. Sparrow

Research output: Contribution to journalReview ArticleOtherpeer-review

26 Citations (Scopus)

Abstract

Despite recent advances, the therapeutic armamentarium for inflammatory bowel disease (IBD) is still limited. In addition, a step-up approach is recommended for most IBD patients. Thus, optimizing each medical therapy before switching to another drug class is the rule in clinical practice. Conventional therapies for IBD have not received the same amount of attention as biologic therapies over the last decade. However, due to their efficacy, safety, and low cost the thiopurine drugs azathioprine and 6-mercaptopurine remain the backbone of therapy for IBD. Pharmacogenomic advances and increased knowledge of their metabolism are allowing dosage optimization. Herein, after describing the pharmacogenetics and pharmacokinetics of thiopurines, we will discuss how to optimize thiopurine therapy. We will then underscore the need to take into account safety issues when optimizing thiopurine treatment.

Original languageEnglish
Pages (from-to)1428-1435
Number of pages8
JournalInflammatory Bowel Diseases
Volume17
Issue number6
DOIs
Publication statusPublished - Jun 2011
Externally publishedYes

Keywords

  • inflammatory bowel disease
  • optimization
  • thiopurines

Cite this